ERBB2 and breast carcinoma: However, in a meta-analysis of 78,984 breast cancer cases across 17 studies summarized by Ciqiu Yang et al., it was reported that breast cancer patients with HER2-low expression had better survival outcomes than those with HER2–0 expression (41).